Sign in

    Kelsey Lucerne

    Research Analyst at William Blair & Company

    There is no verifiable information identifying Kelsey Lucerne as an analyst or holding any position at William Blair & Company. No records, professional profiles, or industry databases list her as a current or former equity research analyst, nor do any sources indicate coverage of specific companies, performance rankings, or securities credentials. Available biographical details indicate that Kelsey Lucerne is known in academic circles for neuroscience research at Mount Sinai and Temple University, with no connection to equity analysis or William Blair. As such, a comprehensive professional profile in the requested context cannot be provided.

    Kelsey Lucerne's questions to Atea Pharmaceuticals (AVIR) leadership

    Kelsey Lucerne's questions to Atea Pharmaceuticals (AVIR) leadership • Q2 2025

    Question

    Kelsey Lucerne from William Blair & Company inquired about the enrollment progress and investigator enthusiasm for the Phase III C BEYOND and C FORWARD trials.

    Answer

    Chief Medical Officer Dr. Arantxa Horga confirmed that enrollment is on track, with C BEYOND progressing faster due to quicker North American regulatory approvals. She noted that the steady enrollment reflects significant investigator enthusiasm and a strong patient value proposition.

    Ask Fintool Equity Research AI